nach oben

Pediatric Nephrology

Erschienen in:

13.01.2018 | Educational Review

Desensitisation strategies in high-risk children before kidney transplantation

verfasst von: Ankit Sharma, Anne M. Durkan

Erschienen in: Pediatric Nephrology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Transplantation is the preferred modality for renal replacement therapy in children. With increasing rates of re-transplantation within the paediatric population, there are more sensitised children on waiting lists. One issue with developing strategies to treat these children is the number of different definitions of sensitisation. and we would therefore recommend an immunological risk stratification approach.

Methods

We discuss methods of sensitisation prevention, assessment and management, including paired exchange programmes and desensitisation protocols.

Results

There are limited published evidence-based data for desensitisation in adults and none in children; thus, we present information on the available therapies currently in use.

Discussion

Further research is required to investigate strategies which prevent sensitisation in children, including the healthcare utility of incorporating epitope-based matching into organ allocation algorithms. Controlled studies are also needed to establish the most appropriate desensitisation regimen(s).

McDonald SP, Craig JC, Australian and New Zealand Paediatric Nephrology Association (2004) Long-term survival of children with end-stage renal disease. N Engl J Med 350:2654–2662CrossRef

Icard P, Hooper SR, Gipson DS, Ferris ME (2010) Cognitive improvement in children with CKD after transplant. Pediatr Transplant 14:887–890PubMedCentralCrossRef

Franke D, Thomas L, Steffens R, Pavicic L, Gellermann J, Froede K, Querfeld U, Haffner D, Zivicnjak M (2015) Patterns of growth after kidney transplantation among children with ESRD. Clin J Am Soc Nephrol 10:127–134CrossRef

Tjaden LA, Grootenhuis MA, Noordzij M, Groothoff JW (2016) Health-related quality of life in patients with pediatric onset of end-stage renal disease: state of the art and recommendations for clinical practice. Pediatr Nephrol 31:1579–1591CrossRef

Hart A, Smith JM, Skeans MA, Gustafson SK, Stewart DE, Cherikh WS, Wainright JL, Kucheryavaya A, Woodbury M, Snyder JJ, Kasiske BL, Israni AK (2017) OPTN/SRTR 2015 annual data report: kidney. Am J Transplant 17 [Suppl 1]:21–116PubMedCentralCrossRef

Holmberg C, Jalanko H (2016) Long-term effects of paediatric kidney transplantation. Nat Rev Nephrol 12:301–311CrossRef

Van Arendonk KJ, Boyarsky BJ, Orandi BJ, James NT, Smith JM, Colombani PM, Segev DL (2014) National trends over 25 years in pediatric kidney transplant outcomes. Pediatrics 133:594–601PubMedCentralCrossRef

Lamb KE, Lodhi S, Meier-Kriesche HU (2011) Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 11:450–462CrossRef

Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D (2000) Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342:605–612CrossRef

10.

Ritchie AG, Clayton PA, McDonald SP, Kennedy SE (2017) Age-specific risk of renal graft loss from late acute rejection or noncompliance in the adolescent and young adult period. Nephrology. https://doi.org/10.1111/nep.13067 CrossRef

11.

Van Arendonk KJ, James NT, Boyarsky BJ, Garonzik-Wang JM, Orandi BJ, Magee JC, Smith JM, Colombani PM, Segev DL (2013) Age at graft loss after pediatric kidney transplantation: exploring the high-risk age window. Clin J Am Soc Nephrol 8:1019–1026PubMedCentralCrossRef

12.

Rees L, Kim JJ (2015) HLA sensitisation: can it be prevented? Pediatr Nephrol 30:577–587CrossRef

13.

Zachary AA, Hart JM, Lucas DP, Leffell MS (2007) The co$t of mi$matching. Clin Transpl 2007:261–269

14.

Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL (2011) Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 365:318–326CrossRef

15.

Orandi BJ, Luo X, Massie AB, Garonzik-Wang JM, Lonze BE, Ahmed R, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Gaber AO, Montgomery RA, Segev DL (2016) Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med 374:940–950PubMedCentralCrossRef

16.

Lim WH, Chadban SJ, Clayton P, Budgeon CA, Murray K, Campbell SB, Cohney S, Russ GR, McDonald SP (2012) Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients. Clin Transpl 26:E428–E437CrossRef

17.

Susal C, Opelz G (2013) Current role of human leukocyte antigen matching in kidney transplantation. Curr Opin Organ Transplant 18:438–444CrossRef

18.

Gralla J, Tong S, Wiseman AC (2013) The impact of human leukocyte antigen mismatching on sensitization rates and subsequent retransplantation after first graft failure in pediatric renal transplant recipients. Transplantation 95:1218–1224CrossRef

19.

Reynolds BC, Tinckam KJ (2017) Sensitization assessment before kidney transplantation. Transplant Rev (Orlando) 31:18–28CrossRef

20.

Kramer CSM, Roelen DL, Heidt S, Claas FHJ (2017) Defining the immunogenicity and antigenicity of HLA epitopes is crucial for optimal epitope matching in clinical renal transplantation. HLA 90:5–16CrossRef

21.

Duquesnoy RJ (2011) Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications. Tissue Antigens 77:525–534CrossRef

22.

Duquesnoy RJ, Marrari M (2011) Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants. Transpl Immunol 24:164–171CrossRef

23.

Duquesnoy RJ, Takemoto S, de Lange P, Doxiadis II, Schreuder GM, Persijn GG, Claas FH (2003) HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A,B amino acid triplet level on kidney transplant survival. Transplantation 75:884–889CrossRef

24.

Wiebe C, Pochinco D, Blydt-Hansen TD, Ho J, Birk PE, Karpinski M, Goldberg A, Storsley LJ, Gibson IW, Rush DN, Nickerson PW (2013) Class II HLA epitope matching-a strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 13:3114–3122CrossRef

25.

Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II (2004) The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 78:190–193CrossRef

26.

Duquesnoy RJ (2016) Reflections on HLA epitope-based matching for transplantation. Front Immunol 7:469PubMedCentralCrossRef

27.

Kausman JY, Walker AM, Cantwell LS, Quinlan C, Sypek MP, Ierino FL (2016) Application of an epitope-based allocation system in pediatric kidney transplantation. Pediatr Transplant 20:931–938CrossRef

28.

Bryan CF, Chadha V, Warady BA (2016) Donor selection in pediatric kidney transplantation using DR and DQ eplet mismatching: a new histocompatibility paradigm. Pediatr Transplant 20:926–930CrossRef

29.

Pradhan M, Raffaelli RM, Lind C, Meyers KE, Kaplan BS, Baluarte HJ, Monos D (2008) Successful deceased donor renal transplant in a sensitized pediatric recipient with the use of plasmapheresis. Pediatr Transplant 12:711–716CrossRef

30.

Stojanovic J, Adamusiak A, Kessaris N, Chandak P, Ahmed Z, Sebire NJ, Walsh G, Jones HE, Marks SD, Mamode N (2017) Immune desensitization allows pediatric blood group incompatible kidney transplantation. Transplantation 101:1242–1246CrossRef

31.

Zhang Q, Reed EF (2016) The importance of non-HLA antibodies in transplantation. Nat Rev Nephrol 12:484–495PubMedCentralCrossRef

32.

Carroll R, Coates PT (2015) Does rituximab help in HLA desensitization for kidney transplantation? Kidney Int 87:277–279CrossRef

33.

Keith DS, Vranic GM (2016) Approach to the highly sensitized kidney transplant candidate. Clin J Am Soc Nephrol 11:684–693PubMedCentralCrossRef

34.

Orandi BJ, Garonzik-Wang JM, Massie AB, Zachary AA, Montgomery JR, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Gaber AO, Montgomery RA, Segev DL (2014) Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant 14:1573–1580CrossRef

35.

Cecka JM (2010) Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant 10:26–29CrossRef

36.

(2017) NHS Blood and Transplant: Relative Chance of Transplant Calculator. Available from https://www.odt.nhs.uk/transplantation/. Accessed December 2017

37.

Patel R, Terasaki PI (1969) Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280:735–739CrossRef

38.

Ferrari P, Woodroffe C, Cantwell L (2015) Australian Paired Kidney Exchange (AKX) programme: Biannual Report #6. Available from http://www.donatelife.gov.au/about-us/kidney-exchange-programme. Accessed December 2017

39.

Manook M, Koeser L, Ahmed Z, Robb M, Johnson R, Shaw O, Kessaris N, Dorling A, Mamode N (2017) Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis. Lancet 389:727–734CrossRef

40.

Sethi S, Choi J, Toyoda M, Vo A, Peng A, Jordan SC (2017) Desensitization: overcoming the immunologic barriers to transplantation. J Immunol Res 2017:6804678PubMedCentralCrossRef

41.

Vo AA, Sinha A, Haas M, Choi J, Mirocha J, Kahwaji J, Peng A, Villicana R, Jordan SC (2015) Factors predicting risk for antibody-mediated rejection and graft loss in highly human leukocyte antigen sensitized patients transplanted after desensitization. Transplantation 99:1423–1430CrossRef

42.

Tambur AR, Herrera ND, Haarberg KM, Cusick MF, Gordon RA, Leventhal JR, Friedewald JJ, Glotz D (2015) Assessing antibody strength: comparison of MFI, C1q, and titer information. Am J Transplant 15:2421–2430CrossRef

43.

Viglietti D, Loupy A, Vernerey D, Bentlejewski C, Gosset C, Aubert O, Duong van Huyen JP, Jouven X, Legendre C, Glotz D, Zeevi A, Lefaucheur C (2017) Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss. J Am Soc Nephrol 28:702–715CrossRef

44.

Mohan S, Palanisamy A, Tsapepas D, Tanriover B, Crew RJ, Dube G, Ratner LE, Cohen DJ, Radhakrishnan J (2012) Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 23:2061–2071PubMedCentralCrossRef

45.

Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J (2004) Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15:3256–3262CrossRef

46.

Ejaz NS, Shields AR, Alloway RR, Sadaka B, Girnita AL, Mogilishetty G, Cardi M, Woodle ES (2013) Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients. Am J Transplant 13:3142–3154CrossRef

47.

Vo AA, Jordan SC (2014) Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy. Clin Exp Immunol 178 [Suppl 1]:48–51PubMedCentralCrossRef

48.

Vo AA, Choi J, Kim I, Louie S, Cisneros K, Kahwaji J, Toyoda M, Ge S, Haas M, Puliyanda D, Reinsmoen N, Peng A, Villicana R, Jordan SC (2015) A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation 99:2356–2363CrossRef

49.

Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231CrossRef

50.

Paquin Proulx D, Aubin E, Lemieux R, Bazin R (2010) Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin Immunol 135:422–429CrossRef

51.

Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J (2002) Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2:758–760CrossRef

52.

Jordan SC, Toyoda M, Vo AA (2011) Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol 7:341–348CrossRef

53.

Glotz D, Haymann JP, Sansonetti N, Francois A, Menoyo-Calonge V, Bariety J, Druet P (1993) Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 56:335–337CrossRef

54.

Jordan S, Cunningham-Rundles C, McEwan R (2003) Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 3:653–664CrossRef

55.

Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing JC, Medeiros A, Tyler S, Mekala D, Cochran E, Sarvaiya H, Garofalo K, Meccariello R, Meador JW 3rd, Rutitzky L, Schultes BC, Ling L, Avery W, Nimmerjahn F, Manning AM, Kaundinya GV, Bosques CJ (2015) Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A 112:E1297–E1306PubMedCentralCrossRef

56.

Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC (2008) Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359:242–251CrossRef

57.

Macklin PS, Morris PJ, Knight SR (2014) A systematic review of the use of rituximab for desensitization in renal transplantation. Transplantation 98:794–805CrossRef

58.

Vo AA, Choi J, Cisneros K, Reinsmoen N, Haas M, Ge S, Toyoda M, Kahwaji J, Peng A, Villicana R, Jordan SC (2014) Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation 98:312–319CrossRef

59.

Jackson AM, Kraus ES, Orandi BJ, Segev DL, Montgomery RA, Zachary AA (2015) A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int 87:409–416CrossRef

60.

Van den Hoogen MW, Kamburova EG, Baas MC, Steenbergen EJ, Florquin S, Koenen HJPM, Joosten I, Hilbrands LB (2015) Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant 15:407–416

61.

Hwang SD, Chung BH, Oh EJ, Choi BS, Park CW, Kim YS, Yang CW (2015) Effect of pretransplant rituximab use on posttransplant clinical outcomes in patients with high panel reactive antibody scores. Nephron 130:239–244CrossRef

62.

Shaffer D, Feurer ID, Crowe D, Schaefer H (2016) Early and sustained reduction in donor-specific antibodies in desensitized living donor kidney transplant recipients: a 3-year prospective study. Transplant Direct 2:e62PubMedCentralCrossRef

63.

Kahwaji J, Jordan SC, Najjar R, Wongsaroj P, Choi J, Peng A, Villicana R, Vo A (2016) Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab. Transpl Int 29:1276–1285CrossRef

64.

Kahwaji J, Sinha A, Toyoda M, Ge S, Reinsmoen N, Cao K, Lai CH, Villicana R, Peng A, Jordan S, Vo A (2011) Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 6:2894–2900PubMedCentralCrossRef

65.

Toyoda M, Thomas D, Ahn G, Kahwaji J, Mirocha J, Chu M, Vo A, Suviolahti E, Ge S, Jordan SC (2015) JC polyomavirus viremia and progressive multifocal leukoencephalopathy in human leukocyte antigen-sensitized kidney transplant recipients desensitized with intravenous immunoglobulin and rituximab. Transpl Infect Dis 17:838–847CrossRef

66.

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101–1110CrossRef

67.

Bologna L, Gotti E, Da Roit F, Intermesoli T, Rambaldi A, Introna M, Golay J (2013) Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 190:231–239CrossRef

68.

Taube DH, Williams DG, Cameron JS, Bewick M, Ogg CS, Rudge CJ, Welsh KI, Kennedy LA, Thick MG (1984) Renal transplantation after removal and prevention of resynthesis of HLA antibodies. Lancet 1:824–828CrossRef

69.

Schwenger V, Morath C (2010) Immunoadsorption in nephrology and kidney transplantation. Nephrol Dial Transplant 25:2407–2413CrossRef

70.

Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Maldonado AQ, Harland RC, Terasaki PI (2014) Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Transplantation 97:494–501CrossRef

71.

Lefaucheur C, Viglietti D, Bentlejewski C, Duong van Huyen JP, Vernerey D, Aubert O, Verine J, Jouven X, Legendre C, Glotz D, Loupy A, Zeevi A (2016) IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol 27:293–304CrossRef

72.

Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE (2000) Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70:887–895CrossRef

73.

Sonnenday CJ, Ratner LE, Zachary AA, Burdick JF, Samaniego MD, Kraus E, Warren DS, Montgomery RA (2002) Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 34:1614–1616CrossRef

74.

Haririan A, Nogueira J, Kukuruga D, Schweitzer E, Hess J, Gurk-Turner C, Jacobs S, Drachenberg C, Bartlett S, Cooper M (2009) Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 9:536–542CrossRef

75.

Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S (2006) A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6:346–351CrossRef

76.

Akalin E, Dinavahi R, Friedlander R, Ames S, de Boccardo G, Sehgal V, Schroppel B, Bhaskaran M, Lerner S, Fotino M, Murphy B, Bromberg JS (2008) Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 3:1160–1167PubMedCentralCrossRef

77.

Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD (2009) Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 9:201–209CrossRef

78.

Woodle ES, Shields AR, Ejaz NS, Sadaka B, Girnita A, Walsh RC, Alloway RR, Brailey P, Cardi MA, Abu Jawdeh BG, Roy-Chaudhury P, Govil A, Mogilishetty G (2015) Prospective iterative trial of proteasome inhibitor-based desensitization. Am J Transplant 15:101–118CrossRef

79.

Jeong JC, Jambaldorj E, Kwon HY, Kim MG, Im HJ, Jeon HJ, In JW, Han M, Koo TY, Chung J, Song EY, Ahn C, Yang J (2016) Desensitization using Bortezomib and high-dose immunoglobulin increases rate of deceased donor kidney transplantation. Medicine (Baltimore) 95:e2635CrossRef

80.

Sberro-Soussan R, Zuberl J, Suberbielle-Boissel C, Legendre C (2010) Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment. Clin Transpl 2010:409–414

81.

Guthoff M, Schmid-Horch B, Weisel KC, Haring HU, Konigsrainer A, Heyne N (2012) Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transpl Immunol 26:171–175CrossRef

82.

Revollo JY, Cuffy MC, Abu Jawdeh BG, Paterno F, Girnita A, Brailey P, Alloway RR, Woodle ES (2015) Case report: successful living donor kidney transplantation in a highly human leukocyte antigen-sensitized recipient with a positive Cytotoxic Crossmatch using Bortezomib-based desensitization without intravenous immunoglobulin. Transplant Proc 47:2254–2257CrossRef

83.

Kwun J, Burghuber C, Manook M, Iwakoshi N, Gibby A, Hong JJ, Knechtle S (2017) Humoral compensation after bortezomib treatment of allosensitized recipients. J Am Soc Nephrol 28:1991–1996PubMedCentralCrossRef

84.

Schmidt N, Alloway RR, Walsh RC, Sadaka B, Shields AR, Girnita AL, Hanseman DJ, Woodle ES (2012) Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation 94:352–361CrossRef

85.

Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448–457CrossRef

86.

Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6:a016295PubMedCentralCrossRef

87.

Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Perez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gamir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F, Paediatric Rheumatology International Trials Organisation PRINTO; Pediatric Rheumatology Collaborative Study Group (PRCSG) (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74:1110–1117CrossRef

88.

Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Fremeaux-Bacchi V, Mejean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X (2013) Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 369:1215–1226CrossRef

89.

Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11:2405–2413CrossRef

90.

Cornell LD, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD (2015) Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 15:1293–1302CrossRef

91.

Chehade H, Rotman S, Matter M, Girardin E, Aubert V, Pascual M (2015) Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient. Pediatrics 135:e551–e555CrossRef

92.

Jordan SC, Choi J, Kahwaji J, Vo A (2016) Complement inhibition for prevention and treatment of antibody-mediated rejection in renal allograft recipients. Transplant Proc 48:806–808CrossRef

93.

Burbach M, Suberbielle C, Brocheriou I, Ridel C, Mesnard L, Dahan K, Rondeau E, Hertig A (2014) Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 98:1056–1059CrossRef

94.

Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA (2014) Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 98:857–863CrossRef

95.

Vo AA, Zeevi A, Choi J, Cisneros K, Toyoda M, Kahwaji J, Peng A, Villicana R, Puliyanda D, Reinsmoen N, Haas M, Jordan SC (2015) A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation 99:299–308CrossRef

96.

Jordan SCJ, Zhang X, Haas M, Peng A, Kahwaji J, Villicana R, Vo A (2016) Initial experience with the bacterial enzyme IdeS (IgG endopeptidase) for desensitization of highly-HLA sensitized (HS) patients. Am J Transplant 16:796–797

97.

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP (2016) Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374:333–343CrossRef

98.

Quinlan C, Awan A, Gill D, Waldron M, Little D, Hickey D, Conlon P, Keogan M (2011) Pediatric renal transplantation in a highly sensitised child—8 years on. Case Rep Transplant 2011:370596

99.

Adamusiak AM, Stojanovic J, Shaw O, Vaughan R, Sebire NJ, Drage M, Kessaris N, Marks SD, Mamode N (2017) Desensitization protocol enabling pediatric crossmatch-positive renal transplantation: successful HLA-antibody-incompatible renal transplantation of two highly sensitized children. Pediatr Nephrol 32:359–364CrossRef

100.

Al-Uzri AY, Seltz B, Yorgin PD, Spier CM, Andreoni K (2002) Successful renal transplant outcome after intravenous gamma-globulin treatment of a highly sensitized pediatric recipient. Pediatr Transplant 6:161–165CrossRef

101.

Pirojsakul K, Desai D, Lacelle C, Seikaly MG (2016) Management of sensitized pediatric patients prior to renal transplantation. Pediatr Nephrol 31:1691–1698CrossRef

102.

Valentini RP, Nehlsen-Cannarella SL, Gruber SA, Mattoo TK, West MS, Lang C, Imam AA (2007) Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients. Pediatr Transplant 11:77–81CrossRef

103.

Van Arendonk KJ, Garonzik Wang JM, Deshpande NA, James NT, Smith JM, Montgomery RA, Colombani PM, Segev DL (2013) Practice patterns and outcomes in retransplantation among pediatric kidney transplant recipients. Transplantation 95:1360–1368PubMedCentralCrossRef

Titel: Desensitisation strategies in high-risk children before kidney transplantation
verfasst von: Ankit Sharma
Anne M. Durkan
Publikationsdatum: 13.01.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Nephrology / Ausgabe 12/2018
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-017-3882-2

Neu im Fachgebiet Pädiatrie

16.04.2024 | Stillen, Säuglingsnahrung, Beikost | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Desensitisation strategies in high-risk children before kidney transplantation

Abstract

Background

Methods

Results

Discussion

Neu im Fachgebiet Pädiatrie

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Komplexes Krankheitsbild zwischen Haut und Lunge – und das mit 13 Jahren

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Angeborene Herzfehler: Viele sind später körperlich oder kognitiv eingeschränkt

Update Pädiatrie

Springer Medizin

Abstract

Background

Methods

Results

Discussion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2018

Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study

Diagnosis and management of bladder bowel dysfunction in children with urinary tract infections: a position statement from the International Children’s Continence Society

Does idiopathic hypercalciuria affect bone metabolism during childhood? A prospective case-control study

Treatment strategies for children with steroid-dependent nephrotic syndrome: in need of controlled studies

The light at the end of the tunnel: an unusual case of acute kidney injury in a pediatric patient: Questions

Pre-operative level of FGF23 predicts severe acute kidney injury after heart surgery in children

Neu im Fachgebiet Pädiatrie

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Komplexes Krankheitsbild zwischen Haut und Lunge – und das mit 13 Jahren

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Angeborene Herzfehler: Viele sind später körperlich oder kognitiv eingeschränkt

Update Pädiatrie